Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

ww.trubion.com" target="_new">http://www.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's ability to successfully conduct clinical trials for TRU-015, TRU-016 and other SMIP(TM) product candidates, the uncertainty of the FDA approval process and other regulatory requirements, the therapeutic and commercial value of Trubion's drug candidates, the company's Wyeth collaboration, including its ability to receive milestone payments from Wyeth, and risks associated with defending and enforcing any patent claims or other intellectual property rights; and such other risks as identified in the company's quarterly report on Form 10-Q for the period ended September 30, 2007, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate website at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

TRBN-G

Contact:

Jim DeNike<
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 DNA vaccine pioneer ... in its development of JRC-LAMP-vax, an innovative and safe ... Phase IC studies began this month in Hawaii, moving ... fever. , The Japanese red cedar releases pollen that ... Japan. Mountain Cedar pollen wreaks similar havoc in Colorado, ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... Fertilizer Industryā€¯ is a professional and in-depth ... The report provides basic Seaweed Fertilizer information, ... industry chain structure as well as industry ... analysis, including domestic market as well as ...
(Date:8/21/2014)... 21, 2014 Telomere Biosciences, LLC (Telomere ... "TELO-20 for Dogs" with Telomerase Activation Complex ... the world for dogs. Telomeres are the protective ... the body. A wealth of ground-breaking research by ... Science and Aging, including Nobel laureates, has demonstrated ...
(Date:8/21/2014)... -- Mathematic studies at the Program for Evolutionary Dynamics ... the Jeffrey Epstein VI Foundation , have shown that ... for elimination. These aggressive cells are the driver mutations that ... map of what to look for when examining tumors, comes ... cells can be extracted from biopsy, it,s very difficult to ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2
... 3, 2010 ... ... var shortURL = ""; ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
... Sequenom, Inc. (Nasdaq: SQNM ) today ... of research and development, will present an overview of ... (Logo:   http://photos.prnewswire.com/prnh/20040415/SQNMLOGO ) (Logo: ... Renshaw 12th Annual Healthcare Conference Location: The ...
... at ESC 2010 Further Support the Benefit of The... -- STOCKHOLM, September 2, 2010 ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Biology Technology:New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 2New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 3New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 4New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 5New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 6New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 7New Report - U.S. Digestive Health Ingredients Markets (2010 - 2015) - MarketsandMarkets 8Sequenom to Present at Two Financial Conferences in September 2Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 2Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 3Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 4Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 5Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 6Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 7Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 8Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups 9
(Date:8/21/2014)... , Aug. 21, 2014 Nxt-ID, Inc. ... growing mobile commerce market, announced today that its shares ... stock to be issued in its proposed underwritten public ... for listing on The Nasdaq Capital Market, subject to ... common stock and warrants, and will trade under the ...
(Date:8/21/2014)... study aimed at improving the food intake, health and ... homes is among three projects at the University of ... the Canadian Institutes of Health Research (CIHR). , ... Sciences at Waterloo, and a Schlegel research chair in ... to investigate why many Canadians living in long-term care ...
(Date:8/21/2014)... , Saturday to Wednesday, Oct. 18-22, 2014 , ... W. Harbor Drive, San Diego, CA 92101 , ... and other presentations of the latest research in ... plenary session featuring high-scoring abstracts on rare genetic ... various cancers, and treatment for sun sensitivity (Saturday, ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2
... is available in French . MONTREAL, August ... slower but rather wiser than young brains, which allows older ... undertaken at the University Geriatrics Institute of Montreal by Dr. ... Montreal. "The older brain has experience and knows that nothing ...
... your best bet when it comes to losing that dreaded ... Medical Center researchers conducted a head-to-head comparison of aerobic exercise, ... aerobic exercise to be the most efficient and most effective ... your health. This isn,t the fat that lies just ...
... waters off the North Carolina coast, historically-significant World War ... testament to a relatively unknown chapter in U.S. history. ... not only important for their cultural value, but also ... and algal species. Additionally, due to their unique location ...
Cached Biology News:Clinical study shows young brains lack the wisdom of their elders 2Aerobic exercise bests resistance training at burning belly fat 2